SpringWorks Therapeutics Inc
NASDAQ:SWTX

Watchlist Manager
SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Watchlist
Price: 49.77 USD -2.18% Market Closed
Market Cap: 3.7B USD
Have any thoughts about
SpringWorks Therapeutics Inc?
Write Note

During the last 3 months SpringWorks Therapeutics Inc insiders have not bought any shares, and sold 15m USD worth of shares. The stock price has increased by 31% over this period (open performance analysis).

The last transaction was made on Mar 3, 2025 by Edris Badreddin (Senior Vice President of Pharmacology and Toxicology) , who sold 208.4k USD worth of SWTX shares.

Last Transactions:
Islam Saqib
Co-Founder and Chief Technology Officer
$-625k
Edris Badreddin
Senior Vice President of Pharmacology and Toxicology
$-208.4k
Lynch Daniel
Chief Executive Officer
$-2.6m
Islam Saqib
Co-Founder and Chief Technology Officer
$-1.5m
Ashar Bhavesh
Chief Financial Officer
$-62.2k
Lynch Daniel
Chief Executive Officer
$-24k
Islam Saqib
Co-Founder and Chief Technology Officer
$-639.5k
Lynch Daniel
Chief Executive Officer
$-3.7m
Islam Saqib
Co-Founder and Chief Technology Officer
$-2.6m
Hambleton Julie
Chief Financial Officer
$-730.2k
Edris Badreddin
Senior Vice President of Pharmacology and Toxicology
$-1.6m
Pichl Daniel
Chief Financial Officer
$-729k
Edris Badreddin
Senior Vice President of Pharmacology and Toxicology
$-499.9k
Islam Saqib
Co-Founder and Chief Technology Officer
$-1.9m
Edris Badreddin
Senior Vice President of Pharmacology and Toxicology
$-493.4k
Islam Saqib
Co-Founder and Chief Technology Officer
$-1.3m
Islam Saqib
Co-Founder and Chief Technology Officer
$-1.3m
Hambleton Julie
Chief Financial Officer
$-116.1k
Edris Badreddin
Senior Vice President of Pharmacology and Toxicology
$-463.8k
Pichl Daniel
Chief Financial Officer
$-751.5k
Ashar Bhavesh
Chief Financial Officer
$-47.6k
Pichl Daniel
Chief Financial Officer
$-405.9k
Hambleton Julie
Chief Financial Officer
$-70.9k
Hambleton Julie
Chief Financial Officer
$-64.6k
Schwartz Jeffrey Lawrence
Chief Executive Officer
$-49.9m
Hambleton Julie
Chief Financial Officer
$-34.8k
Pichl Daniel
Chief Financial Officer
$-26.6k
Orbimed Advisors Llc
$-4m
Orbimed Advisors Llc
Director
$-7.9m
Islam Saqib
Co-Founder and Chief Technology Officer
$-591.5k
Islam Saqib
Co-Founder and Chief Technology Officer
$-2.2m
Smith L. Mary
Chief Financial Officer
$-559.7k
View All Transactions

During the last 3 months SpringWorks Therapeutics Inc insiders have not bought any shares, and sold 15m USD worth of shares. The stock price has increased by 31% over this period (open performance analysis).

The last transaction was made on Mar 3, 2025 by Edris Badreddin (Senior Vice President of Pharmacology and Toxicology) , who sold 208.4k USD worth of SWTX shares.

Sold
0-3
months
15m USD
6
3-6
months
2.4m USD
2
6-9
months
1.8m USD
2
9-12
months
1.9m USD
3
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

SpringWorks Therapeutics Inc
Insider Trading Chart

SpringWorks Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

SpringWorks Therapeutics Inc
Glance View

Market Cap
3.7B USD
Industry
Biotechnology

SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.

SWTX Intrinsic Value
45 USD
Overvaluation 10%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top